Article
Author(s):
Adverum Biotechnologies announces topline 52-week results from LUNA Phase 2 trial and 4-year OPTIC results
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Recent changes to cornea: Preferred Practice Patterns
Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD
Innovation and the clinician-scientist
FDA accepts NDA from Aldeyra Therapeutics for reproxalap for dry eye